PhaseV to Showcase New AI/ML-Powered Clinical Trial Design and Analysis Capabilities at CMO Summit 360⁰

Company to Demonstrate Latest Advancements in Causal Machine Learning and AI for Trial Design and Predictive Analysis for Clinical Trial Success

BOSTON, March 24, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, announced today that it will demonstrate new capabilities of its platform for clinical trials at the upcoming Chief Medical Officer (CMO) Summit 360⁰ in Boston, MA.

The new tools allow clinical development leaders such as CMOs, biostatisticians, and clinical operations professionals to seamlessly integrate learnings from previous clinical trials into trial design for future studies, bridging two processes that have traditionally been conducted separately.

"For the first time, clinical teams can leverage causal ML-driven insights from prior trials and real-world data to inform the design of future trials - all within a single, end-to-end multi-modal platform," said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. "This approach enables real-time evaluation of various parameters and their impact in order to increase the probability of success. By turning data analysis into actionable insights, we're helping biotech and pharma companies reduce failure rates, optimize trial investments and improve patient outcomes."

PhaseV's Causal to Adaptive capability integrates real-world and clinical trial data to improve planning, efficiency, and decision-making for future clinical trials. The Clinical Trial Success Prediction capability enables trial sponsors to quantify the probability of success by analyzing historical trial data, trial parameters and real-world evidence. By applying PhaseV's proprietary statistical and AI methodologies to complex trial and patient datasets, this tool generates a probability score that supports more informed decision-making, reduces failure rates, and ultimately improves patient outcomes.

"Integrating causal ML and AI capabilities with Bayesian adaptive tools is unique and significantly more advanced than existing solutions currently available on the market," said Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV. "Our platform is a true game-changer for the industry."

Live demos of PhaseV's Causal to Adaptive and Clinical Trial Success Prediction capabilities will be conducted at the CMO Summit 360⁰ in Boston at Booth #11 from April 7–8. For more information or to request a meeting at the conference, please contact [email protected].

About PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions.

PhaseV's platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of trial success by up to 30%.

To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.

Learn more at www.PhaseVTrials.com and follow us on LinkedIn.

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
[email protected]
929-588-2008

Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg

SOURCE PhaseV